CN114403443A - Drop pill containing astaxanthin and preparation method thereof - Google Patents
Drop pill containing astaxanthin and preparation method thereof Download PDFInfo
- Publication number
- CN114403443A CN114403443A CN202210131314.XA CN202210131314A CN114403443A CN 114403443 A CN114403443 A CN 114403443A CN 202210131314 A CN202210131314 A CN 202210131314A CN 114403443 A CN114403443 A CN 114403443A
- Authority
- CN
- China
- Prior art keywords
- astaxanthin
- parts
- pill
- dripping
- dropping
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 72
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 72
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 72
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 72
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 72
- 239000006187 pill Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 235000012055 fruits and vegetables Nutrition 0.000 claims abstract description 15
- 239000011159 matrix material Substances 0.000 claims abstract description 15
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 14
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 14
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 14
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 14
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 10
- 239000003765 sweetening agent Substances 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 22
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000008118 PEG 6000 Substances 0.000 claims description 13
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 11
- 229940057995 liquid paraffin Drugs 0.000 claims description 11
- 239000004386 Erythritol Substances 0.000 claims description 10
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 10
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 10
- 235000019414 erythritol Nutrition 0.000 claims description 10
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 10
- 229940009714 erythritol Drugs 0.000 claims description 10
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 10
- 239000000811 xylitol Substances 0.000 claims description 10
- 235000010447 xylitol Nutrition 0.000 claims description 10
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 10
- 229960002675 xylitol Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000001509 sodium citrate Substances 0.000 claims description 9
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000003094 microcapsule Substances 0.000 claims description 8
- 241000168517 Haematococcus lacustris Species 0.000 claims description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 3
- 239000005457 ice water Substances 0.000 claims description 3
- 239000000845 maltitol Substances 0.000 claims description 3
- 235000010449 maltitol Nutrition 0.000 claims description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 3
- 229940035436 maltitol Drugs 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000001508 potassium citrate Substances 0.000 claims description 3
- 229960002635 potassium citrate Drugs 0.000 claims description 3
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 3
- 235000011082 potassium citrates Nutrition 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- 235000011083 sodium citrates Nutrition 0.000 claims description 3
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 229960002920 sorbitol Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000009758 senescence Effects 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
- 229930003268 Vitamin C Natural products 0.000 description 7
- 235000015165 citric acid Nutrition 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- 239000004376 Sucralose Substances 0.000 description 6
- 235000020197 coconut milk Nutrition 0.000 description 6
- 235000019408 sucralose Nutrition 0.000 description 6
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229930189775 mogroside Natural products 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- -1 other carotenoids Chemical compound 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a dropping pill containing astaxanthin and a preparation method thereof, which comprises the following components in parts by weight: 2-11 parts of astaxanthin, 2-8 parts of beta-nicotinamide mononucleotide, 40-80 parts of water-soluble matrix, 0.04-0.2 part of sweetening agent, 2-20 parts of functional sugar alcohol, 3-15 parts of fruits and vegetables, 0.05-0.5 part of antioxidant, 0-3.0 parts of essence, 0.1-1.0 part of sour agent and 0.05-0.5 part of acid-base balance regulator. The drop pill prepared by the invention has stable performance, convenient carrying and pure and beautiful taste, can still keep the original astaxanthin efficacy, and has the biological efficacy of resisting oxidation, improving immunity, delaying senescence and inhibiting free radicals.
Description
Technical Field
The invention belongs to the technical field of health care products, and particularly relates to a dropping pill containing astaxanthin and a preparation method thereof.
Background
Astaxanthin, also known as astaxanthin or astaxanthin, is a carotenoid and a strong natural antioxidant. Astaxanthin, like other carotenoids, is a fat-soluble and water-soluble pigment, and has a strong antioxidant capacity 550 times that of vitamin E and 10 times that of beta-carotene. The molecular structure of the astaxanthin contains 13 conjugated double bonds, hydroxyl and unsaturated ketone groups existing on a terminal ring structure and alpha-hydroxyketone consisting of the hydroxyl and the ketone groups, the multiple unsaturated double bond structure of the astaxanthin determines that the astaxanthin is easy to degrade and oxidize under the action of light, oxygen and heat, and meanwhile, the astaxanthin extracted from haematococcus pluvialis exists in the form of ester, the content of the astaxanthin accounts for about 5 percent of that of astaxanthin oil, so that the astaxanthin cannot be directly applied to an aqueous environment, and the utilization rate of the astaxanthin is reduced.
The drop pill is a pellet preparation prepared by heating, melting and mixing solid or liquid medicine and appropriate substance (generally called matrix), dripping into immiscible condensate, and shrinking and condensing. The preparation method of the dripping pill has the advantages of simple equipment, convenient operation, contribution to labor protection, short process period, high productivity, easily controlled process conditions, stable quality, accurate dosage, short heating time, easy oxidation and increased stability after the volatile medicine is dissolved in the matrix. However, the pill has small drug-loading rate, low corresponding drug content and large dosage, and simultaneously, the selected matrix and condensing agent are less, so that the variety of the pill is limited, and not all effective components can be prepared into the pill.
In recent years, studies have been made to investigate the effect of storage and processing conditions on the stability of astaxanthin, confirming that the stability and bioavailability of astaxanthin can be improved by controlling the processing and formulation conditions. The existing astaxanthin preparation formulation comprises a soft capsule, a dispersing agent, micro/nano particles and an emulsifying agent. However, no relevant report is found in the research of preparing astaxanthin into the dropping pill.
Disclosure of Invention
The invention aims to provide an astaxanthin dropping pill which has stable performance, convenient carrying and pure and beautiful taste, can still keep the original astaxanthin efficacy, and has the biological efficacies of resisting oxidation, improving immunity, delaying senility and inhibiting free radicals.
In order to solve the technical problems, the invention provides the following technical scheme:
the invention provides an astaxanthin dripping pill which comprises the following components in parts by weight: 2-11 parts of astaxanthin, 2-8 parts of beta-nicotinamide mononucleotide, 40-80 parts of water-soluble matrix, 0.04-0.2 part of sweetening agent, 2-20 parts of functional sugar alcohol, 3-15 parts of fruits and vegetables, 0.05-0.5 part of antioxidant, 0-3.0 parts of essence, 0.1-1.0 part of sour agent and 0.05-0.5 part of acid-base balance regulator.
Preferably, the astaxanthin is one or two of astaxanthin microcapsule powder and haematococcus pluvialis powder.
Preferably, the water-soluble matrix comprises one or more of PEG4000, PEG6000, sodium stearate, water and glycerol.
Preferably, the functional sugar alcohol comprises one or more of erythritol, xylitol, mannitol, maltitol and sorbitol.
Preferably, the acid-base balance regulator comprises one or more of sodium chloride, sodium citrate, potassium chloride and potassium citrate.
The invention provides a preparation method of an astaxanthin dripping pill, which comprises the following steps:
(1) pouring astaxanthin, beta-nicotinamide mononucleotide, sweetener, functional sugar alcohol, fruits and vegetables, antioxidant, essence, acidity regulator and acid-base balance regulator into water-soluble matrix, heating and stirring to obtain dripping pill;
(2) dripping the dropping liquid of the dropping pill into liquid paraffin to obtain the astaxanthin dropping pill.
Preferably, the dropping height in the step (2) is 5-20 cm.
Preferably, the dropping temperature in the step (2) is 70-100 ℃.
Preferably, the inner diameter of the dropping pipe for dropping in the step (2) is 1.0-2.0 mm, and the outer diameter is 2.0-4.0 mm.
Preferably, the liquid paraffin in step (2) is cooled by an ice water bath.
Compared with the prior art, the invention has the following beneficial effects:
the astaxanthin is prepared into the dropping pill for the first time, and the prepared dropping pill has stable performance, convenient carrying, pure and beautiful taste, small health and safety risk and easy storage; can still maintain the original astaxanthin efficacy, and has biological effects of resisting oxidation, improving immunity, delaying aging, and inhibiting free radicals.
The astaxanthin dropping pill prepared by the method has the advantages of simple process, no dust, low production cost and good industrial practicability.
Drawings
Figure 1 is a flow chart of the preparation of astaxanthin dropping pills.
Detailed Description
The invention provides an astaxanthin dripping pill which is characterized by comprising the following components in parts by weight: 2-11 parts of astaxanthin, 2-8 parts of beta-nicotinamide mononucleotide, 40-80 parts of water-soluble matrix, 0.04-0.2 part of sweetening agent, 2-20 parts of functional sugar alcohol, 3-15 parts of fruits and vegetables, 0.05-0.5 part of antioxidant, 0-3.0 parts of essence, 0.1-1.0 part of sour agent and 0.05-0.5 part of acid-base balance regulator. The sources of the components are not particularly limited in the present invention, and commercially available products known to those skilled in the art may be used.
In the present invention, the astaxanthin is preferably 3 to 11 parts by weight, and more preferably 10 parts by weight. The astaxanthin is preferably astaxanthin microcapsule powder or one or two of astaxanthin microcapsule powder and haematococcus pluvialis powder, and is more preferably astaxanthin microcapsule powder. In the invention, the haematococcus pluvialis powder is haematococcus pluvialis wall-broken powder.
In the invention, the weight part of the beta-nicotinamide mononucleotide is preferably 3-5 parts, and more preferably 4.25 parts. The beta-nicotinamide mononucleotide of the invention has the functions of delaying senility, promoting blood flow and heart health, preventing neurological diseases and resisting obesity and diabetes.
In the present invention, the water-soluble base is preferably 65 to 75 parts by weight, and more preferably 72.12 parts by weight. In the invention, the water-soluble matrix is preferably one or more of PEG4000, PEG6000, sodium stearate, water and glycerol, and more preferably PEG6000, water and glycerol. As an embodiment, when the water-soluble matrix is PEG6000, water and glycerin, the PEG6000 is preferably 61.43 parts by weight, the water is preferably 4.58 parts by weight, and the glycerin is preferably 6.11 parts by weight.
In the present invention, the weight part of the sweetener is preferably 0.05 to 0.1 part, and more preferably 0.09 part. The sweetening agent in the invention is preferably one or more of acesulfame potassium, saccharin sodium, mogroside, neotame, aspartame, stevioside and sucralose, and is more preferably sucralose.
In the present invention, the weight part of the functional sugar alcohol is preferably 6 to 15 parts, and more preferably 11.04 parts. In the present invention, the functional sugar alcohol is preferably one or more of erythritol, xylitol, mannitol, maltitol, and sorbitol, and more preferably two of erythritol and xylitol. As an embodiment, when the functional sugar alcohols are erythritol and xylitol, the weight part of erythritol is preferably 2 to 10 parts, more preferably 4.25 parts, and the weight part of xylitol is preferably 2 to 10 parts, more preferably 6.79 parts. The functional sugar alcohol has low heat, does not stimulate insulin secretion, does not cause blood sugar rise and obesity, and can prevent dental caries.
In the invention, the weight part of the fruits and vegetables is preferably 5-10 parts, and more preferably 8.49 parts. The fruit and vegetable of the invention is preferably one or more of fruit and vegetable powder, fruit and vegetable juice and fruit and vegetable extract, and more preferably fruit and vegetable powder. As an implementation mode, the fruits and vegetables are coconut milk raw powder, and the weight part of the coconut milk raw powder is 8.49 parts.
In the invention, the antioxidant is preferably 0.08-0.3 part by weight, and more preferably 0.1 part by weight. In the invention, the antioxidant is preferably one or more of vitamin C, tea polyphenol, vitamin E, bamboo leaf antioxidant, licorice antioxidant, rosemary extract, green tea extract and carotenoid, and more preferably vitamin C. As an embodiment, the vitamin C is 0.1 part by weight.
In the invention, the essence is preferably 0.2-2.5 parts by weight, and more preferably 0.5 part by weight. The essence is preferably natural plant essence.
In the invention, the weight part of the sour agent is preferably 0.2-0.8 part, and more preferably 0.4 part. In the present invention, the acidulant is preferably one or more of citric acid, lactic acid, tartaric acid, acetic acid, malic acid, and gluconic acid, and more preferably citric acid. As an embodiment, the citric acid is 0.4 parts by weight.
In the invention, the weight part of the acid-base balance regulator is preferably 0.08-0.3 part, and more preferably 0.1 part. The acid-base balance regulator in the invention is preferably one or more of sodium chloride, sodium citrate, potassium chloride and potassium citrate, and more preferably sodium citrate. As one possible embodiment, the sodium citrate is 0.1 part by weight.
The invention provides a preparation method of the astaxanthin dropping pill, which comprises the following steps:
(1) pouring astaxanthin, beta-nicotinamide mononucleotide, sweetener, functional sugar alcohol, fruits and vegetables, antioxidant, essence, acidity regulator and acid-base balance regulator into water-soluble matrix, heating and stirring to obtain dripping pill;
(2) dripping the dropping liquid of the dropping pill into cooled liquid paraffin to obtain the astaxanthin dropping pill.
In the present invention, the water-soluble matrix is preferably three of PEG6000, water and glycerin. As an implementation mode, the PEG6000 needs to be melted at high temperature, the melted PEG6000 is uniformly mixed with the astaxanthin, the beta-nicotinamide mononucleotide, the sweetener, the functional sugar alcohols, the fruits and vegetables, the antioxidant, the essence, the sour agent and the acid-base balance regulator to ensure that all the components are completely melted, and then water and glycerol are added to be heated and uniformly mixed.
In the invention, the melting temperature is 90-100 ℃.
The dripping temperature of the dripping pill is preferably 70-100 ℃, and more preferably 70-85 ℃; the preferred dripping height is 5-20 cm, and the more preferred dripping height is 10-15 cm; the inner diameter of the dripping pipe for dripping is 1.0-2.0 mm, more preferably 1.5mm, and the outer diameter is 2.0-4.0 mm, more preferably 3.0 mm; the dripping height is the distance between the dropper and the liquid paraffin horizontal plane. In the invention, the constant temperature and the hydrostatic pressure of the dropping liquid are kept constant in the dropping process. In the invention, proper dropping temperature, dropping height and inner and outer diameters of a dropper used for dropping are set, so that dropping pills with uniform particle weight and particle size and good smoothness and roundness can be obtained, and the original activity of astaxanthin can be maintained.
In the present invention, the temperature of the liquid paraffin is preferably cooled by ice-water bath. The dropping pill prepared by the invention can slowly float upwards or sink in the liquid paraffin, so that the prepared dropping pill is well formed.
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1
The astaxanthin dropping pill of the embodiment comprises the following components in parts by weight:
10 parts of astaxanthin microcapsule powder, 600061.43 parts of PEG, 0.09 part of sucralose, 4.25 parts of erythritol, 6.79 parts of xylitol, 8.49 parts of coconut milk raw powder, 4.25 parts of beta-nicotinamide mononucleotide, 0.4 part of citric acid, 0.1 part of sodium citrate, 0.1 part of vitamin C, 4.58 parts of water and 6.11 parts of glycerol.
The preparation method of the astaxanthin dropping pill comprises the following steps:
(1) heating the PEG6000 in parts by weight in an oven or a water bath kettle to 95 ℃ to melt the PEG6000 to obtain molten PEG 6000;
(2) uniformly mixing the astaxanthin microcapsule powder, beta-nicotinamide mononucleotide, sucralose, erythritol, xylitol, coconut milk raw powder, citric acid, sodium citrate and vitamin C in parts by weight, pouring the mixture into molten PEG6000, and uniformly stirring at 70-85 ℃ to melt the mixture to obtain dropping pills;
(3) placing the beaker filled with the liquid paraffin in a cold water basin containing an ice bag to obtain cooled liquid paraffin;
(4) dripping the dripping pill into cooled liquid paraffin with a dropper with inner diameter of 1.5mm and outer diameter of 3.0mm, maintaining the temperature of the dropper mouth at 70 deg.C and the height of the dropper at 15cm to obtain astaxanthin dripping pill.
Example 2
The astaxanthin dropping pill of the embodiment comprises the following components in parts by weight:
4.25 parts of astaxanthin microcapsule powder, 600070.24 parts of PEG, 0.1 part of sucralose, 4.25 parts of erythritol, 6.79 parts of xylitol, 6.74 parts of coconut milk raw powder, 5 parts of beta-nicotinamide mononucleotide, 0.2 part of citric acid, 0.1 part of sodium citrate, 0.2 part of vitamin C, 2.74 parts of water and 5.36 parts of glycerol.
The preparation method of the astaxanthin dropping pill in the embodiment is different from the embodiment 1 in that the heating temperature in the step (1) is 100 ℃, the dropper mouth temperature in the step (4) is 65 ℃, and the dropper height is 12 cm; the other steps were the same as in example 1.
Example 3
The astaxanthin dropping pill of the embodiment comprises the following components in parts by weight:
7.5 parts of haematococcus pluvialis wall-breaking powder, 600065.21 parts of PEG, 0.2 part of sucralose, 3.27 parts of erythritol, 14.23 parts of xylitol, 5.48 parts of coconut milk raw powder, 3.78 parts of beta-nicotinamide mononucleotide, 0.6 part of citric acid, 0.4 part of sodium citrate, 0.2 part of vitamin C, 2 parts of water and 4.5 parts of glycerol.
The preparation method of the astaxanthin dropping pill of the embodiment is different from the embodiment 1 in that the heating temperature in the step (1) is 90 ℃, the dropper mouth temperature in the step (4) is 75 ℃, the dropper height is 18cm, and other steps are the same as the embodiment 1.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (10)
1. An astaxanthin dripping pill is characterized by comprising the following components in parts by weight: 2-11 parts of astaxanthin, 2-8 parts of beta-nicotinamide mononucleotide, 40-80 parts of water-soluble matrix, 0.04-0.2 part of sweetening agent, 2-20 parts of functional sugar alcohol, 3-15 parts of fruits and vegetables, 0.05-0.5 part of antioxidant, 0-3.0 parts of essence, 0.1-1.0 part of sour agent and 0.05-0.5 part of acid-base balance regulator.
2. The astaxanthin drop pill of claim 1, wherein the astaxanthin is one or both of astaxanthin microcapsule powder and haematococcus pluvialis powder.
3. The astaxanthin drop pill of claim 1, wherein the water soluble matrix comprises one or more of PEG4000, PEG6000, sodium stearate, water, glycerol.
4. The astaxanthin drop pill of claim 1, wherein the functional sugar alcohol comprises one or more of erythritol, xylitol, mannitol, maltitol, and sorbitol.
5. The astaxanthin drop pill of claim 1, wherein the acid-base balance regulator comprises one or more of sodium chloride, sodium citrate, potassium chloride and potassium citrate.
6. The method for preparing an astaxanthin dripping pill according to any one of claims 1 to 5, comprising the following steps:
(1) pouring astaxanthin, beta-nicotinamide mononucleotide, sweetener, functional sugar alcohol, fruits and vegetables, antioxidant, essence, acidity regulator and acid-base balance regulator into water-soluble matrix, heating and stirring to obtain dripping pill;
(2) dripping the dropping liquid of the dropping pill into liquid paraffin to obtain the astaxanthin dropping pill.
7. The method for preparing an astaxanthin dripping pill according to claim 6, wherein the dripping height in the step (2) is 5-20 cm.
8. The method for preparing an astaxanthin dripping pill according to claim 6, wherein the dripping temperature in the step (2) is 70-100 ℃.
9. The method for producing an astaxanthin dropping pill according to claim 6, wherein the inner diameter of the dropping pill for dropping in the step (2) is 1.0 to 2.0mm, and the outer diameter thereof is 2.0 to 4.0 mm.
10. The method for preparing an astaxanthin dripping pill according to claim 6, wherein the liquid paraffin in the step (2) is cooled in an ice-water bath.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210131314.XA CN114403443A (en) | 2022-02-14 | 2022-02-14 | Drop pill containing astaxanthin and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210131314.XA CN114403443A (en) | 2022-02-14 | 2022-02-14 | Drop pill containing astaxanthin and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114403443A true CN114403443A (en) | 2022-04-29 |
Family
ID=81278716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210131314.XA Pending CN114403443A (en) | 2022-02-14 | 2022-02-14 | Drop pill containing astaxanthin and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114403443A (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105725184A (en) * | 2016-02-02 | 2016-07-06 | 北京同仁堂健康药业股份有限公司 | Composition containing haematococcus pluvialis and collagen and preparing method thereof |
CN107753445A (en) * | 2016-08-18 | 2018-03-06 | 江苏康缘药业股份有限公司 | A kind of bilobalide K dripping pill and preparation method thereof |
CN111888464A (en) * | 2020-08-06 | 2020-11-06 | 朱洪滨 | A health composition with antiaging and immunity enhancing effects |
CN112515070A (en) * | 2020-11-11 | 2021-03-19 | 云南爱尔康生物技术有限公司 | Sports beverage containing astaxanthin, taurine, nicotinamide mononucleotide and electrolyte and preparation method thereof |
CN113262237A (en) * | 2021-06-09 | 2021-08-17 | 云南维他源生物科技有限公司 | AGNM composition, preparation and application thereof |
-
2022
- 2022-02-14 CN CN202210131314.XA patent/CN114403443A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105725184A (en) * | 2016-02-02 | 2016-07-06 | 北京同仁堂健康药业股份有限公司 | Composition containing haematococcus pluvialis and collagen and preparing method thereof |
CN107753445A (en) * | 2016-08-18 | 2018-03-06 | 江苏康缘药业股份有限公司 | A kind of bilobalide K dripping pill and preparation method thereof |
CN111888464A (en) * | 2020-08-06 | 2020-11-06 | 朱洪滨 | A health composition with antiaging and immunity enhancing effects |
CN112515070A (en) * | 2020-11-11 | 2021-03-19 | 云南爱尔康生物技术有限公司 | Sports beverage containing astaxanthin, taurine, nicotinamide mononucleotide and electrolyte and preparation method thereof |
CN113262237A (en) * | 2021-06-09 | 2021-08-17 | 云南维他源生物科技有限公司 | AGNM composition, preparation and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3087279C (en) | Composition containing cannabidiol/cannabis extract and caffeine, and application of composition | |
TW200815046A (en) | Composition containing reduced coenzyme Q10 and production method thereof | |
CN103262931B (en) | The hard candy of water-soluble lutein ester, its preparation method and containing water-soluble lutein ester | |
KR102151371B1 (en) | Food Composition for Preventing and Improving Diabetes Mellitus Comprising Fermented Noni and Method for Preparing the Same | |
CN106912668A (en) | A kind of grape seed extract lutein ester pressed candy and preparation method | |
CN108208815A (en) | Blueberry and the double-colored composite sheet of lutein ester and preparation method thereof | |
KR101874462B1 (en) | Composition for preventing, ameliorating or treating atopic dermatitis comprising Schisandra chinensis leaf extract as effective component | |
CN106615516A (en) | Candy containing phaffia rhodozyma astaxanthin and preparation method thereof | |
JP6459206B2 (en) | Superabsorbent ubiquinol formulation | |
CN104223260A (en) | Solid health beverage containing resveratrol microcapsule and fructo-oligosaccharide | |
WO2014188861A1 (en) | Gel-like composition having high ubiquinol content | |
KR101018061B1 (en) | Jujube jam and manufacturing method thereof | |
CN114403443A (en) | Drop pill containing astaxanthin and preparation method thereof | |
JP2005198645A (en) | Fermented liquid of tomato, hypotensive agent, method for producing the same, and eating and drinking composition | |
CN104432355A (en) | Method for preparing blueberry functional beverage and blueberry health care capsules | |
CN110235977A (en) | A kind of sandwich soft sweets and preparation method thereof | |
CN114522142A (en) | Nano stabilizer and preparation method and application thereof | |
KR20120056379A (en) | Method for producing Dangmyen with enhanced antioxidative activity adding purple sweet potato and Dangmyen produced by the same method | |
KR101853711B1 (en) | Cosmetic compositions for improving of skin comprising the extract of Piper cambodianum | |
JP6584794B2 (en) | Food in containers containing acetic acid bacteria or pulverized products thereof | |
CN112691150A (en) | Composition and preparation method and application thereof | |
CN111357907A (en) | Health food for maintaining beauty and keeping young and preparation method thereof | |
JPH0698729A (en) | Ginseng extract-containing beverage and its production | |
JP2014195477A (en) | Method for stably and transparently dispersing emulsified perfume composition within high-concentration alcohol | |
KR101719057B1 (en) | A Beverage Containing Extract and Slice of Spend Mushroom (Flammulina Velutipes) and A Method For Preparing Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |